Skip to main content
BetterLife Pharma logo

BetterLife Pharma — Investor Relations & Filings

Ticker · BETR CSE Professional, scientific and technical activities
Open in API
Filings indexed 282 across all filing types
Latest filing 2025-06-18 Share Issue/Capital Cha…
Country CA Canada
Listing CSE BETR

About BetterLife Pharma

https://abetterlifepharma.com/

BetterLife Pharma is an emerging biotechnology company focused on developing and commercializing novel, patient-friendly compounds to treat neuro-psychiatric and neurological disorders, addressing significant unmet mental health needs. The company's core strategy involves revolutionizing brain health by producing non-hallucinogenic medicines. Its lead product candidate is 2-Bromo-LSD (BETR-001), a second-generation lysergic acid diethylamide (LSD) derivative. BETR-001 is designed to mimic the projected therapeutic properties of LSD, acting as a potent neuroplastogen, but without causing psychedelic effects or incurring the high regulatory hurdles associated with Schedule 1 controlled substances. BETR-001 is being developed as a potential therapy for debilitating conditions such as treatment-resistant depression, PTSD, anxiety, and cluster headaches.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Share Issue/Capital Change Classification · 1% confidence The document is a corporate press release issued by BetterLife Pharma announcing two primary items: (1) an Issue Notification from the USPTO for a composition of matter patent and (2) the issuance of 6,473,712 common shares and 6,473,712 share purchase warrants pursuant to conversion of debentures. The notice of new share issuance (and associated warrants) constitutes an announcement of a share capital change rather than a full financing round or detailed financial results. Therefore, it falls squarely under “Share Issue/Capital Change” (SHA).
2025-06-18 English
Material change report - English.pdf
Regulatory Filings Classification · 1% confidence The document is entitled “FORM 51-102F3 – MATERIAL CHANGE REPORT” filed under Canadian National Instrument 51-102, detailing a material change (scientific update, corporate share issuance, audited financial statement filing, etc.). It is a specific regulatory filing rather than an annual or quarterly report, earnings release or other transaction notice. There is no dedicated category for a Canadian material change report, making it a general regulatory announcement. Therefore it falls under the fallback category “Regulatory Filings (RNS).”
2025-05-30 English
News release - English.pdf
Director's Dealing Classification · 1% confidence The document is a press release focused on the CEO’s beneficial ownership corrections and the CEO’s personal share transactions (direct investment and salary settlement). It is not an annual or interim report, not an AGM or earnings release, nor a notice of dividend, capital change or M&A. Instead, it details insider share dealings by a director. Therefore, it should be classified as a Director’s Dealing (DIRS).
2025-05-22 English
Report of exempt distribution (45-106F1).pdf
Management Reports Classification · 1% confidence The document is titled “Management Discussion & Analysis” for the quarter ended March 31, 2025. It provides management’s narrative on results, business trends, forward-looking statements, and analysis of quarterly performance. It is a standalone MD&A, not a full interim report with financial statements. This aligns directly with the “Management Reports” category (Code: MDA).
2025-05-07 English
Material change report - English.pdf
Transaction in Own Shares Classification · 1% confidence The document is a Canadian Form 51-102F3 “Material Change Report” describing grant of options and issuance of shares pursuant to warrant exercises and debt settlement. This is a regulatory disclosure of the company issuing its own shares. Under our taxonomy, announcements of share issuances fall under “Transaction in Own Shares” (POS).
2025-05-06 English
News release - English.pdf
Share Issue/Capital Change Classification · 1% confidence The document is a corporate press release announcing share issuances to settle debt and under exercise of warrants, representing a change in the company’s capital structure via new share issues. This fits squarely under “Share Issue/Capital Change” rather than a general earnings release or annual/interim report. Therefore, the appropriate classification is SHA.
2025-05-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.